Skip to main content
. 2011 Dec 22;33(3):644–651. doi: 10.1093/carcin/bgr308

Fig. 3.

Fig. 3.

Effect of oral supplementation of PFE in TRAMP on PI3K/Akt/mTOR signaling and IGF-I/IGFBP-3 levels. (A, B) Oral PFE (0.1 and 0.2% in drinking water ad libitum) was initiated in animals at 6 weeks of age as described in the text. A control group that received water alone was run in parallel. At 12 weeks of age, the dorsolateral prostate was dissected, tissue lysates prepared and subjected to immunoblotting. Five samples from each group were analyzed by immunoblotting under identical conditions; however, only two bands representative of the variation in expression within each groups are shown. The blots were stripped and reprobed for analysis of β-actin to determine equal loading of the protein. (C) Histograms represent IGF-I/IGFBP-3 ratios (mean ± SE) in serum of control and PFE-supplemented animals. At 12, 20 and 34 weeks of age, blood was collected and serum separated for estimation of IGF-I and IGFBP-3 levels. The ratios were determined from the data obtained from analyses of IGF-I and IGFBP levels in serum. *P < 0.05, **P < 0.01. (D) Immunoblot representing protein expression of T-antigen in control and PFE-supplemented mice evaluated at 12 weeks of age. The blots were stripped and reprobed for analysis of β-actin to determine equal loading of the protein.